This simple blood test, potentially can assess your individual risk for developing lung cancer prior to the appearance of symptoms.
The Future of EarlyCDT™
EarlyCDT uses patented technology to detect cancer in its early stages when the possibility of a cure is highest. No other methodology currently offers this kind of “power to know.” Oncimmune’s first product—EarlyCDT–Lung—will soon be followed by tests for solid–tumor cancers such as those of the breast, colon, prostate, stomach, pancreas and ovaries. This on–going research and production provides a strong investment opportunity with excellent prospects for future growth.
Over the past 5 years £23m ($35m) has been invested by Nottingham University, Balderton Capital Management which is one of the largest venture capital funds in Europe, senior employees and a number of private individuals, in developing the product and its associated technology.
Oncimmune (USA) LLC | 8960 Commerce Drive Building #6 | De Soto, Kansas 66018 | 888.583.9030